In recent years, it has become clear that members of the signal transducer and activator of transcription (STAT) family of genes play an important role in cancer. The STAT family consists of seven genes, STAT1-4, STAT5A, STAT5B and STAT6, that are involved in regulating cellular proliferation, apoptosis, angiogenesis and the immune system response. Constitutive activation of STAT3, via mutational changes, is important in oncogenesis in both solid and hematopoietic cancers. In the case of hematopoietic neoplasms, STAT3 driver mutations have been described in T-cell large granular lymphocytic (T-LGL) leukemia and chronic natural killer lymphoproliferative disorders (CLPD-NK) and are seen in 30%-40% of T-LGL leukemia patients.
enhancement and inhibition because persistent stimulation of STAT can result in both malignancy, autoimmune inflammatory diseases. 3, 5, 6 In addition, recent studies have shown that STAT3 not only regulates gene expression by acting as a transcription factor but regulates gene expression ultimately through epigenetic mechanisms such as DNA methylation and chromatin modification. 1 The JAK part of JAK-STAT pathway is well researched and JAK mutations and their importance in pathogenesis of hematological disorders are well studied, with JAK2 V617F being the most well-known mutation, which is detected in the majority of myeloproliferative neoplasms, such as polycythemia vera, primary myelofibrosis and essential thrombocytosis. Numerous JAK-STAT pathway inhibitors have been developed; for instance, the JAK1/2 inhibitor ruxolitinib is approved for treatment of polycythemia vera and primary myelofibrosis, and the pan-JAK inhibitor tofacitinib has also been used in treatment of rheumatologic diseases. 2, 5 Studies have also demonstrated that STAT3 may be the ultimate downstream target of JAK inhibitors and in a study by Chen et al, 7 it was demonstrated that 
| OVERVIEW AND INCIDENCE OF SOMATIC STAT GENE MUTATIONS IN CANCER
The STAT proteins all consist of the same 6 domains ( STAT3 is predominantly mutated in hematopoietic neoplasms, especially in T-LGL leukemia where a high mutation rate (30%-40%)
is observed and in CLPD-NK (Figure 2 ) .
In addition to its role in oncogenesis, STAT3 is also involved in Figure 3 . 12 As expected, STAT3 is the most frequently mutated gene from the STAT family in hematopoietic cancers, followed by STAT5B. STAT1 is unexpectedly the most frequently mutated in melanoma, followed by STAT5B and STAT4, even though the overall occurrence of STAT mutations is low in all entities other than T-LGL and CLPD-NK (Figures 2 and 3 ). 12 3 | GE NETICS AND PATHOLOGIC
FEATURES OF CANCERS WITH STAT GENE MUTATIONS
Here we review the mutational status of STAT3 and STAT5B in T-
LGL, CLPD-NK, aggressive B and T cell lymphomas, melanoma and other tumors, with emphasis on T-LGL leukemia and CLPD-NK, where STAT3 mutational status is useful as a diagnostic marker. caused by neutropenia are seen more frequently. [15] [16] [17] STAT3 is the first molecular marker that is highly specific for T-LGL leukemia, and several mutational hotspots have been detected in 30%-40% of T-LGL leukemia patients and in one-third of the patients with CLPD-NK; a smaller subset of T-LGL leukemia patients (2%) have STAT5B mutations. [18] [19] [20] [21] [22] [23] In a study by Fasan et al, 18 a cohort of 55 patients with unselected TCR rearrangements were studied and STAT3 mutations were detected in 72.7% of the patients (40 out of 55).
In most T-LGL leukemia cases, a clonal expansion of CD8 + large granular lymphocytes exists, with a smaller subset originating from
LGLs. In a study by Andersson et al, 24 STAT5B mutations were detected in 55% (6 of 11 patients) of the patients with CD4 + T-LGL leukemia and no STAT5B mutation was detected in CD8 + T-LGL leukemia. The authors of this study concluded that STAT5B mutations are more unique for the CD4 + phenotype than for the CD8 + phenotype. Clinically, these patients had an indolent disease, which argues against previous assumptions about a more clinically aggressive disease in T-LGL leukemia patients with STAT5B mutations. 24 Larger cohorts need to be studied to confirm a potential correlation between the CD4 + phenotype and existence of STAT5B mutations, and to determine the clinical course in this group of patients. 24 As described above, STAT3 is mutated in 30%-40% of T-LGL cases and STAT3 mutational hotspots are mainly located in the SH2 domain, as shown in Figure 4 . However, more recently, in a study by
Andersson et al, activating STAT3 mutations were also detected in the DBD and the coiled-coil domain in a cohort of patients without F I G U R E 1 Signal transducer and activator of transcription (STAT) family members: 7 proteins that all consist of the same 6 domains: amino acid length is indicated on the right for each member. SH2, Scr homology domain 2; TAD, transactivation domain
LGL (T-cell large granular lymphocytic) leukemia, CLPD-NK (chronic NK lymphoproliferative disorder), 18, 19, [21] [22] [23] 26 PTCL-NOS (peripheral Tcell lymphomas not otherwise specified), 52 ALCL (anaplastic large Tcell lymphoma) 34, 36 and DLBCL (Diffuse large B cell lymphoma). Despite the high mutational frequency of STAT3 mutations in T-
LGL leukemia and CLPD-NK, there are some studies that question the role of the STAT3 mutations as the driver mutations in this entity. In a study by Dutta et al, for instance, it was demonstrated that expression of the STAT3 mutations were insufficient to induce
LGL leukemia in mice models, and it was suggested that STAT3 survival and progression free survival. 32 It has even been suggested that these patients are molecularly distinct from pSTAT3 (À) DLBCL patients and may benefit from molecularly targeted therapy against STAT3. 32 Immunohistochemistry can be helpful to detect nuclear expression of STAT3 in DLBCL patients to identify a subgroup of patients with poorer clinical outcome who can be given a more aggressive treatment from the beginning. However, more research needs to be done to determine the significance of pSTAT3 expression in DLBCL patients and whether the presence of pSTAT3 worsens these patients' prognosis. 
| Melanoma
Melanoma is a genomic unstable disease and has the highest basal mutation rate of any cancer sequenced to date. Different driver mutations have been discovered for this disease, with discovery of BRAF V600E mutation in over 50% of melanomas in 2002 being perhaps most important. 39 While most STAT genes are not mutated in any significant frequency in melanoma, surprisingly, based on COSMIC data, several STAT genes show relevant mutational frequencies: STAT1 (6.93%) followed by STAT5B (5.3%), STAT4 (4.95%) and STAT3 (0.88%), as shown in Figure 3 . Although the mutation rate of STAT genes, in particular STAT3, is not high in melanoma, studies have shown that STAT3 activation plays a role in tumor growth and angiogenesis of melanoma in tumor xenograft studies.
In a study by Xie et al, it was demonstrated that STAT3 activation is higher in brain metastasis than in primary melanoma, suggesting a possible association between STAT3 activation and development of brain metastasis in melanoma patients. STAT3 activity is believed to drive overexpression of the metastatic molecules and thereby contribute to brain metastasis by increasing tumor invasion and angiogenesis. 40 More studies involving melanoma patients need to be conducted to address whether increased levels of STAT3 protein in primary melanoma could indicate development of brain metastasis later in these patients: if this is proven, STAT3 might have potential as a targeted therapy for brain metastasis in melanoma and may improve the prognosis in this patient cohort that usually has a very dismal prognosis.
| Other tumors
The STAT family of genes are not significantly mutated in other cancers beyond those listed above; however, constitutive activation of STAT3 has been identified in head and neck cancers, multiple myeloma as well as breast cancer, prostate cancer, ovarian cancer, GI cancer, and neural tumors such as glioblastoma multiforme (GBM). [41] [42] [43] In recent studies, it has been demonstrated that STAT3 is activated in significantly higher levels in GBM tumor cells than in normal brain cells. The high STAT3 activation seems to be a negative prognostic indicator in GBM, which is the most common primary brain tumor and patients have a dismal prognosis. 43 More research is obviously needed to determine if STAT3 activation plays any role in GBM patients and if it has a negative prognostic effect. 
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